MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

69.59
+3.54
+5.36%
Opening 14:58 05/14 EDT
OPEN
66.74
PREV CLOSE
66.05
HIGH
69.84
LOW
65.72
VOLUME
227.81K
TURNOVER
--
52 WEEK HIGH
100.77
52 WEEK LOW
42.74
MARKET CAP
4.53B
P/E (TTM)
-4.8850
1D
5D
1M
3M
1Y
5Y
BRIEF-Biohaven Pharmaceutical Holding Company Ltd - Nurtec Odt Signs As Primary Partner With Rick Ware Racing For 2021 Ntt Indycar Series Program
reuters.com · 6h ago
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. Nurtec ODT's vibrant colors have already been on display on the No. 51 Honda for the ...
PR Newswire · 7h ago
Pier Capital, LLC Buys Maximus Inc, Axcelis Technologies Inc, Diodes Inc, Sells 1Life ...
GuruFocus News · 22h ago
SVB Leerink Maintains Outperform on Biohaven Pharma Hldgs, Lowers Price Target to $105
SVB Leerink analyst Marc Goodman maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Outperform and lowers the price target from $115 to $105.
Benzinga · 2d ago
--SVB Leerink Adjusts Biohaven Pharmaceutical Holding's Price Target to $105 from $115, Keeps Outperform Rating
MT Newswires · 2d ago
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates (Revised)
Zacks.com · 2d ago
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Zacks · 3d ago
Mizuho Maintains Buy on Biohaven Pharma Hldgs, Lowers Price Target to $90
Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and lowers the price target from $98 to $90.
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHVN. Analyze the recent business situations of Biohaven Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHVN stock price target is 100.55 with a high estimate of 125.00 and a low estimate of 76.00.
EPS
Institutional Holdings
Institutions: 334
Institutional Holdings: 65.21M
% Owned: 100.21%
Shares Outstanding: 65.07M
TypeInstitutionsShares
Increased
78
3.53M
New
50
1.21M
Decreased
88
5.94M
Sold Out
25
2.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.91%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Director
Thomas Lynch
Chairman/Independent Director
Declan Doogan
Chief Executive Officer/Director
Vlad Coric
Chief Financial Officer/Treasurer
James Engelhart
Senior Vice President
Kimberly Gentile
Chief Scientific Officer
Charles Conway
Other
William Jones
Other
Elyse Stock
Other
John Tilton
Independent Director
Gregory Bailey
Independent Director
John Childs
Independent Director
Julia Gregory
Independent Director
Michael Heffernan
Independent Director
Robert Hugin
No Data
  • All
  • Financials
  • Insiders
More
About BHVN
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.

Webull offers kinds of Biohaven Pharmaceutical Holding Co Ltd stock information, including NYSE:BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.